Iron Deficiency in Chronic Thromboembolic Pulmonary Hypertension

Campean, Ioana A; Sadushi-Koliçi, Roela; Beckmann, Hannah Magdalena; Shafran, Inbal; Sajer, Nika Skoro; Lang, Irene

doi:10.1183/13993003.congress-2019.pa1443

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Defined by ferritin <100μg/L or ferritin between 100-299μg/L, transferrin saturation < 20% and raised levels of soluble transferrin receptor (>4.5nmol/L for females, and >5.0nmol/L for males). This correlated with lower exercise capacity but not with haemodynamics or survival (55). Little is known about their role in right ventricular failure.…”

Section: Biomarkers In Pahmentioning

confidence: 90%

“…Iron deficiency is common in those with PH and conveys a worse prognosis [ 52 – 54 ]. At the Congress, C ampean et al [ 55 ] revealed that there was a high prevalence of iron deficiency in 109 (74%) CTEPH patients, defined either by ferritin <100 μg·L −1 , or by ferritin 100–299 μg·L −1 with transferrin saturation <20% and raised levels of soluble transferrin receptor (>4.5 nmol·L −1 for females and >5.0 nmol·L −1 for males). This correlated with lower exercise capacity but not with haemodynamics or survival.…”

Section: Pulmonary Arterial Hypertensionmentioning

confidence: 99%

See 1 more Smart Citation

ERS International Congress, Madrid, 2019: highlights from the Pulmonary Vascular Diseases Assembly

et al. 2020

View full text Add to dashboard Cite

The European Respiratory Society's International Congress of 2019, held in Madrid, Spain had exciting sessions regarding the field of pulmonary vascular disease (PVD). The symposia related to the new ERS/ECS diagnosis and management of acute pulmonary embolism (PE) were well received, as were sessions of pulmonary hypertension (PH) related to lung disease, demonstrating the concept of PH not being the rarity that it was previously thought to be. The use of risk stratification in relation to pulmonary atrial hypertension (PAH) was heavily featured and the scientific sessions informing the respiratory community of potential biomarkers and targets for future therapies were thought provoking.In preparation of the upcoming innovative ERS International Virtual Congress in the autumn of 2020 we wanted to prepare a highlights article of the 2019 PVD sessions as a summary of current knowledge and practise.We have therefore, summarised the key points from the sessions pertaining to the new ERS/ESC guidance of the management of acute PE. We have also focused on prognostic factors and potential therapies in PH related to interstitial lung disease. Relating to PAH we have reviewed the symposia on risk stratification, along with the use on non-invasive measures and the sessions relating to biomarkers in PAH.

show abstract

Section: Biomarkers In Pahmentioning

confidence: 90%